Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer
In this head-to-head causal analysis among ARPI-naïve patients with mCSPC, treatment with apalutamide resulted in better survival outcomes at 24 months compared with enzalutamide. Longer follow-up studies are required to fully determine the therapeutic comparator impact of these agents.
Authors
- Frédéric Kinkead
- Carmine Rossi (ORCID: https://orcid.org/0000-0001-5801-6927)
- Benjamin Lowentritt (ORCID: https://orcid.org/0000-0002-2921-6249)
- Lorie Ellis (ORCID: https://orcid.org/0000-0002-9798-6982)
- Shawn Du (ORCID: https://orcid.org/0000-0003-2896-7873)
- Ibrahim Khilfeh (ORCID: https://orcid.org/0000-0002-7677-2045)
- Neal D. Shore (ORCID: https://orcid.org/0000-0001-5767-0548)
- Dominic Pilon (ORCID: https://orcid.org/0000-0002-6093-7167)
- Lilián Díaz (ORCID: https://orcid.org/0009-0006-6397-0129)
- Mehmet Asim Bilen
Institutions
- Johnson & Johnson (United States) (US)
- Emory University (US)
- Chesapeake Urology Associates (US)
- Carolina Urologic Research Center (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1007/s12325-025-03207-6
- Citations
- 4
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 6.07
Funders
- Janssen Scientific Affairs